Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/JPRN-jRCT2080220353
JPRN-jRCT2080220353UnknownPhase 3

Phase III clinical study of AFT-801 (long-term administration study) Open-label study for excessive daytime sleepiness accompanying obstructive sleep apnea syndrome in CPAP-treated patients

Mitsubishi Tanabe Pharma Alfresa Pharma Corporation0 sitesStarted: February 16, 2007Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 3
Sponsor
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
>= 20age old to <= 70age old (—)
Sex
All

Inclusion Criteria

  • •[Inclusion Criteria]
  • •Patients with a confirmed diagnosis of obstructive sleep apnea syndrome, Patients who have used a CPAP machine for at least three months and are able to continue its use during the study period, Patients aged >=20 and =<70 years, etc.
  • •[Exclusion Criteria]
  • •Patients with existing narcolepsy, periodic limb movement disorder or central sleep apnea syndrome, Patients who work irregular hours or at night, Patients with chronic lack of sleep or irregular bedtime, etc.

Exclusion Criteria

  • Not provided

Investigators

Sponsor
Mitsubishi Tanabe Pharma Alfresa Pharma Corporation

Similar Trials

Unknown
Phase 3
Phase III clinical study of AFT-801 (confirmatory study) Double-blind, placebo-controlled study for excessive daytime sleepiness accompanying obstructive sleep apnea syndrome in CPAP-treated patientsExcessive daytime sleepiness accompanying obstructive sleep apnea syndrome in CPAP-treated patients
JPRN-jRCT2080220352Mitsubishi Tanabe Pharma Alfresa Pharma Corporation
Unknown
Phase 3
Phase 3 clinical study of AFT-801(confirmatory study 0305) Double-blind, placebo-controlled study for excessive daytime sleepiness accompanying obstructive sleep apnea syndrome in CPAP-treated patientsExcessive daytime sleepiness accompanying obstructive sleep apnea syndrome in CPAP-treated patients
JPRN-jRCT2080220749Mitsubishi Tanabe Pharma Alfresa Pharma Corporation
Unknown
Phase 3
AJH801 Phase III Comparative Clinical Study in individuals with essential hypertensioHypertension
JPRN-jRCT2080221447Ajinomoto Pharmaceuticals Co., Ltd.600
Completed
Phase 3
Phase III clinical trial for AT-877 (i.v.) in patients with acute ischemic stroke. Placebo-controlled, double-blind add-on therapy to antiplatelet drugsAcute ischemic stroke (excluding cardioembolic stroke)
JPRN-UMIN000000758Asahi Kasei Pharma Corporation770
Unknown
Phase 2
Early phase II clinical study with AT-877ER in patients with pulmonary arterial hypertensioPulmonary arterial hypertension
JPRN-jRCT2080220801ASAHI KASEI PHARMA CORPORATIO